Search

Displaying results 131 - 140 of 4207 in total
  1. Drug

    Tobramycin

    go.drugbank.com/drugs/DB00684
    ApprovedInvestigational

    [A232294, A232349, L32739, L32749] Tobramycin was approved by the FDA in 1975 and is currently available in a variety of forms for administration by inhalation, injection, and external application to … [A232294, A232299, L32739] However, tobramycin can also be administered intravenously and topically to treat a variety of infections caused by susceptible bacteria.

  2. Drug

    Oxymetholone

    go.drugbank.com/drugs/DB06412
    ApprovedIllicit

    In 2009, no producers of oxymetholone were identified worldwide (SRI 2009), but it was available from 14 suppliers, including 8 U.S. suppliers (ChemSources 2009). … Anabolic-androgenic steroids (AAS), such as oxymetholone, have been abused by bodybuilders and athletes.

  3. Drug

    Gastric intrinsic factor

    go.drugbank.com/drugs/DB09349
    Approved

    However, it is currently in the marketed (but unapproved) product Hematogen in combination with cyanocobalamin (synthetic Vitamin B12), ferrous fumarate, and ascorbic acid for the treatment of anemias … Intrinsic factor (IF), also known as gastric intrinsic factor (GIF), is a glycoprotein produced by the parietal cells of the stomach that is necessary for the absorption of vitamin B12 (cobalamin) later

  4. Drug

    ALTU-135

    go.drugbank.com/drugs/DB05330
    Investigational

    ALTU-135 has been granted orphan drug and fast-track designation as well as CMA Pilot 2 program status by the Food and Drug Administration (FDA). … ALTU-135, the Company's orally administered enzyme replacement therapy for patients with pancreatic insufficiency, is manufactured by blending three drug substance enzymes: lipase, protease and amylase

  5. Drug

    Respiratory syncytial virus vaccine, adjuvanted

    go.drugbank.com/drugs/DB17762
    ApprovedInvestigational

    Arexvy (respiratory syncytial virus vaccine, adjuvanted) is an adjuvanted vaccine developed by GlaxoSmithKline Biologicals. … [L46352] It was also later approved by Health Canada on August 4, 2023,[L47666] and the EMA in March 2025.[L52380]

  6. Drug

    Amantadine

    go.drugbank.com/drugs/DB00915
    ApprovedInvestigational

    The mechanisms of its effects in movement disorders are not well understood but probably reflect an increase in synthesis and release of dopamine, with perhaps some inhibition of dopamine uptake.

  7. Drug

    Prasterone

    go.drugbank.com/drugs/DB01708
    ApprovedInvestigationalNutraceutical

    In Canada, a prescription is required to buy DHEA. … Prasterone, also known as dehydroepiandrosterone (DHEA) is a major C19 steroid produced by the adrenal cortex. It is also produced in small quantities in the testis and the ovary.

  8. Drug

    Opium

    go.drugbank.com/drugs/DB11130
    ApprovedIllicit

    [A32175] Opium is a prohibited drug of abuse in most countries, but the illegal production of this drug and its derivatives keeps being registered. … During the years, opium was used as a sedative and hypnotic, but it was determined to be addictive.[A32171] Opium is extracted from _Papaver somniferum_, which is more known as poppies.

  9. Drug

    Durlobactam

    go.drugbank.com/drugs/DB16704
    ApprovedInvestigational

    [L47336] The combination product of durlobactam and sulbactam was first approved by the FDA in May 2023. … It is typically given in combination with [sulbactam] to protect it from degradation by certain serine-beta-lactamases.

  10. Drug

    Lemborexant

    go.drugbank.com/drugs/DB11951
    ApprovedInvestigational

    [L10863] Recent research in the field of sleep disorders has revealed that insomnia is likely driven not by the inability of the brain to "switch on" sleep-related circuits, but rather an inability to … Lemborexant is a novel dual orexin receptor antagonist used in the treatment of insomnia characterized by difficulties with sleep onset and/or sleep maintenance.